Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.

doi:10.1182/bloodadvances.2024015366

Skip Nav Destination

ERRATUM| January 2, 2025

Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.

Blood Adv (2025) 9 (1): 169.

https://doi.org/10.1182/bloodadvances.2024015366

Page 5309: in Table 2, the point estimates under nonrelapse mortality (NRM) are incorrect in the first 2 rows. The point estimate for “MSD-PTCy” should be “18.5% (14.7-22.5),” not “19.9% (14.7-22.5)”; the point estimate for “Haplo-PTCy” should be “18.6% (16.3-21.0),” not “12.1% (16.3-21.0).” The corrected Table 2 is shown below.

© 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

2025

Table 2.

Multivariate analysis: haploidentical vs MSD, propensity-matched cohort

OS	n	Events	Point estimates	HR	95% CI	P
MSD-PTCy	400	177	57.2% (51.9-62.3)	Ref
Haplo-PTCy	1052	471	59.3% (56.3-62.3)	0.94	0.78-1.14	.54
MSD-PTCy	400	177	57.2% (51.9-62.3)	Ref
Haplo: B-leader–matched	635	275	61.7% (57.8-65.5)	0.89	0.72-1.09	.24
Haplo: B-leader–mismatched	417	196	55.8% (50.9-60.6)	1.04	0.84-1.3	.72
NRM	N	Events	Point estimates	HR	95% CI	P
MSD-PTCy	396	73	18.5% (14.7-22.5)	Ref
Haplo-PTCy	1039	203	18.6% (16.3-21.0)	0.98	0.72-1.32	.87
MSD-PTCy	396	73	18.5% (14.7-22.5)	Ref
Haplo: B-leader–matched	627	109	16.5% (13.7-19.5)	0.83	0.6-1.15	.27
Haplo: B-leader–mismatched	412	94	21.8% (17.9-25.9)	1.21	0.86-1.69	.27
Relapse∗	N	Events	Point estimates	HR	95% CI	P
MSD-PTCy	396	155	38.5% (33.5-43.5)	Ref
Haplo-PTCy	1039	379	34.2% (31.3-37.2)	0.87	0.7-1.08	.20
MSD-PTCy	396	155	38.5% (33.5-43.5)	Ref
Haplo: DRB1–mismatched	887	310	32.9% (29.7-36.0)	0.82	0.66-1.02	.07
Haplo: DRB1–matched	152	69	42.1% (34.0-49.9)	1.14	0.85-1.54	.39
Chronic GVHD	N	Events	Point estimates	HR	95% CI	P
MSD-PTCy	399	131	33.6% (28.8-38.5)	Ref
Haplo-PTCy	1035	333	31.7% (28.9-38.5)	0.99	0.73-1.34	.92
Acute GVHD, grade 2-4†	N	Events	Point estimates	HR	95% CI	P
MSD-PTCy	400	129	32.3% (27.7-36.9)	Ref
Haplo-PTCy	1051	326	31.0% (28.3-33.9)	0.95	0.71-1.27	.74

OS	n	Events	Point estimates	HR	95% CI	P
MSD-PTCy	400	177	57.2% (51.9-62.3)	Ref
Haplo-PTCy	1052	471	59.3% (56.3-62.3)	0.94	0.78-1.14	.54
MSD-PTCy	400	177	57.2% (51.9-62.3)	Ref
Haplo: B-leader–matched	635	275	61.7% (57.8-65.5)	0.89	0.72-1.09	.24
Haplo: B-leader–mismatched	417	196	55.8% (50.9-60.6)	1.04	0.84-1.3	.72
NRM	N	Events	Point estimates	HR	95% CI	P
MSD-PTCy	396	73	18.5% (14.7-22.5)	Ref
Haplo-PTCy	1039	203	18.6% (16.3-21.0)	0.98	0.72-1.32	.87
MSD-PTCy	396	73	18.5% (14.7-22.5)	Ref
Haplo: B-leader–matched	627	109	16.5% (13.7-19.5)	0.83	0.6-1.15	.27
Haplo: B-leader–mismatched	412	94	21.8% (17.9-25.9)	1.21	0.86-1.69	.27
Relapse∗	N	Events	Point estimates	HR	95% CI	P
MSD-PTCy	396	155	38.5% (33.5-43.5)	Ref
Haplo-PTCy	1039	379	34.2% (31.3-37.2)	0.87	0.7-1.08	.20
MSD-PTCy	396	155	38.5% (33.5-43.5)	Ref
Haplo: DRB1–mismatched	887	310	32.9% (29.7-36.0)	0.82	0.66-1.02	.07
Haplo: DRB1–matched	152	69	42.1% (34.0-49.9)	1.14	0.85-1.54	.39
Chronic GVHD	N	Events	Point estimates	HR	95% CI	P
MSD-PTCy	399	131	33.6% (28.8-38.5)	Ref
Haplo-PTCy	1035	333	31.7% (28.9-38.5)	0.99	0.73-1.34	.92
Acute GVHD, grade 2-4†	N	Events	Point estimates	HR	95% CI	P
MSD-PTCy	400	129	32.3% (27.7-36.9)	Ref
Haplo-PTCy	1051	326	31.0% (28.3-33.9)	0.95	0.71-1.27	.74

Full MVA tables are shown in supplemental Table 2.

Haplo, haploidentical; MVA, multivariate analysis; Ref, reference.

∗

Stratified by disease stage.

†

Stratified by race.

Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314. Free

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.